Dear Editor,

Thank you for providing us valuable feedback on our manuscript no. 84174 which will help us to further improve the quality of our manuscript. We have revised our manuscript and are submitting it after revision.

Reviewer 1-

Reviewer #1: The paper submitted for the publication as review, deals with a topic of great interest from clinical as well as biochemical point-of-view: in fact the sepsis represent a very relevant challenge also today However, the content of the paper seems to be totally inadequate and not updated to provide the most important informations about the biomarkers not only those actually used but also those in development. In the present form the review not provide any new and relevant updated informations. Furthermore, the paragraph aimed to describe the usefulness of new technologies, such as metabolomic, is largely incomplete lacking the description of other improved technologies genomic, proteomic, etc that are described in the literature as new diagnostic and prognostic tools in sepsis

Our comments-

The list of biomarkers is exhaustive and the biomarkers described in this review are some of the commonly studied biomarkers and have been included on the expert opinion of all the authors involved based on their detailed evaluation of the data collated from pubmed.

Omics technologies in sepsis may provide valuable new insights that may help in early diagnosis, prognosis and therapeutic modification of sepsis. These technologies (genomics, proteomics, transcriptomics, and metabolomics) have now been described in the revised manuscript in a nutshell, as a detailed review of omics in sepsis is beyond the scope of this review article and would require another review in itself.

Reviewer 2-

Reviewer #2: 1. The epidemiology of sepsis worldwide should be described, including incidence and mortality rates. 2. Diagnostic criteria related to sepsis are not stated. 3. The conclusions do not mention the following: 1. risk factors for sepsis; 2. factors related to disease progression and prognosis; 3. treatment goals, etc.

Our comments-

The epidemiology of sepsis worldwide, including incidence, mortality rates have been incorporated in the introduction of manuscript.
Diagnostic criteria related to sepsis including sepsis and septic shock definitions from Sepsis 3.0 and SIRS criteria have been defined in the revised manuscript.

Tables have now been converted to a standard 3 line format.

The conclusions in the revised manuscript now include treatment goals and the role of biomarkers in the diagnosis of sepsis and incorporates the latest international guidelines on biomarker use (procalcitonin) in sepsis.

We hope that we have been able to edit this manuscript according to the feedback provided by you and the reviewers and are open to further discussions around the review.

Thanking you

Sumit Ray, Director Medical, Holy family hospital, Delhi and Head of Department, Holy family Hospital, delhi (drsrayer67@yahoo.co.in)